Mineral and bone disorder after renal transplantation: a review

Chronic kidney disease–mineral bone disorder is a common clinical picture encountered in patients with end-stage renal disease and is the result of additive pathophysiological processes. Renal transplantation remains the treatment of choice for these patients, especially as advances in this field ha...

Full description

Saved in:
Bibliographic Details
Published in:International urology and nephrology 2008-03, Vol.40 (1), p.171-184
Main Authors: Sadideen, Hazim, Covic, Adrian, Goldsmith, David
Format: Article
Language:English
Subjects:
Adult
Aged
Bone Demineralization, Pathologic - drug therapy
Bone Demineralization, Pathologic - etiology
Humans
Hyperparathyroidism, Secondary - therapy
Kidney Failure, Chronic - surgery
Kidney Transplantation - adverse effects
Medicine
Medicine & Public Health
Middle Aged
Nephrology
Osteoporosis - drug therapy
Osteoporosis - etiology
Parathyroidectomy - adverse effects
Review
Steroids - administration & dosage
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic kidney disease–mineral bone disorder is a common clinical picture encountered in patients with end-stage renal disease and is the result of additive pathophysiological processes. Renal transplantation remains the treatment of choice for these patients, especially as advances in this field have allowed for enhanced allograft survival. However, with increasing success of renal transplantation has come a greater appreciation of some of its subsequent complications, such as posttransplantation bone disease. Recently, persistent hyperparathyroidism and osteopenia–osteoporosis have been given specific attention. Traditionally, persistent hyperparathyroidism has been treated with parathyroidectomy, although the role that calcimimetics may play in the future is promising. Newer aspects to medical management of osteopenia–osteoporosis, such as the efficacy of bisphosphonate therapy and early steroid withdrawal, are becoming apparent and some of the newer drugs for the treatment of osteoporosis are yet to be investigated in this subgroup of patients.
ISSN:0301-1623
1573-2584
DOI:10.1007/s11255-007-9310-y